| Variables | SLE (n=225) | Non-SLE (n=10) | | General characteristics | | | | Age, years, median (range) | 32 (11-69) | 48 (15-68) | | Sex (female/male) | 208/17 | 9/1 | Duration of the primary disease,
years, median (range) | 5.4 (0-33.0) | 2.8 (0-10.0) | | Clinical manifestations, n (%) | | | | Dyspnea | 201/203 (99.0) | 10/10 (100.0) | | Pleuritic chest pain | 127/160 (79.4) | 6/10 (60.0) | | Cough | 38/118 (32.2) | 2/10 (20.0) | | Image, PFT, and EMG findings, n (%) | | | Diaphragm elevation | 186/204 (91.2) | 9/10 (90.0) | | Pleural effusion | 71/204 (34.8) | 5/10 (50.0) | | Atelectasis | 31/204 (15.2) | 7/10 (70.0) | | Pleural thickening | 24/204 (11.7) | 2/10 (20.0) | | PFT restrictive pattern | 198/205 (96.6) | 10/10 (100.0) | | Phrenic nerve desfunction | 3/16 (18.8) | 3/4 (75.0) | | Treatment, n (%) | | | | Glucocorticoids | 166/175 (94.9) | 10/10 (100.0) | | Azathioprine | 46/175 (26.3) | 3/10 (30.0) | | Cyclophosphamide | 33/175 (18.9) | 2/10 (20.0) | | Mycophenolate mofetil | 20/175 (11.4) | 1/10 (10.0) | | Methotrexate | 9/175 (5.1) | 0 | | Rituximab | 18/175 (10.3) | 3/10 (30.0) | | Beliuumab | 2/175 (1.1) | 0 | | Outcome, n (%) | | | | Clinical improvement | 78/106 (73.6) | 10/10 (100.0) | | PFT improvement | 37/68 (54.4) | 6/8 (75.0) | | Image improvement | 10/46 (21.7) | 6/8 (75.0) |
|